WO2001098468A3 - Proteases - Google Patents
Proteases Download PDFInfo
- Publication number
- WO2001098468A3 WO2001098468A3 PCT/US2001/019178 US0119178W WO0198468A3 WO 2001098468 A3 WO2001098468 A3 WO 2001098468A3 US 0119178 W US0119178 W US 0119178W WO 0198468 A3 WO0198468 A3 WO 0198468A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prts
- provides
- proteases
- polynucleotides
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002411971A CA2411971A1 (en) | 2000-06-16 | 2001-06-13 | Proteases |
EP01948379A EP1292684A2 (en) | 2000-06-16 | 2001-06-13 | Proteases |
AU2001269836A AU2001269836A1 (en) | 2000-06-16 | 2001-06-13 | Proteases |
JP2002504617A JP2004515217A (en) | 2000-06-16 | 2001-06-13 | Protease |
US10/311,035 US20040023243A1 (en) | 2001-06-13 | 2001-06-13 | Proteases |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21233600P | 2000-06-16 | 2000-06-16 | |
US60/212,336 | 2000-06-16 | ||
US21395500P | 2000-06-22 | 2000-06-22 | |
US60/213,955 | 2000-06-22 | ||
US21539600P | 2000-06-29 | 2000-06-29 | |
US60/215,396 | 2000-06-29 | ||
US21682100P | 2000-07-07 | 2000-07-07 | |
US60/216,821 | 2000-07-07 | ||
US21894600P | 2000-07-14 | 2000-07-14 | |
US60/218,946 | 2000-07-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001098468A2 WO2001098468A2 (en) | 2001-12-27 |
WO2001098468A3 true WO2001098468A3 (en) | 2003-01-03 |
Family
ID=27539651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/019178 WO2001098468A2 (en) | 2000-06-16 | 2001-06-13 | Proteases |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1292684A2 (en) |
JP (1) | JP2004515217A (en) |
AU (1) | AU2001269836A1 (en) |
CA (1) | CA2411971A1 (en) |
WO (1) | WO2001098468A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859741B2 (en) | 2007-08-23 | 2014-10-14 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US8999341B1 (en) | 2014-07-15 | 2015-04-07 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9062105B1 (en) | 2014-07-15 | 2015-06-23 | Kymab Limited | Precision Medicine by targeting VEGF-A variants for treatment of retinopathy |
US9109034B1 (en) | 2014-07-15 | 2015-08-18 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
US9266961B2 (en) | 2012-06-15 | 2016-02-23 | Genentech, Inc. | Anti-PCSK9 antibodies, formulations, dosing, and methods of use |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030096391A1 (en) * | 2000-12-22 | 2003-05-22 | Millennium Pharmaceuticals, Inc. | 17903, a novel human aminopeptidase and uses therefor |
US6716613B1 (en) * | 1999-11-11 | 2004-04-06 | Yamanouchi Pharmaceutical Co., Ltd. | Metalloprotease having aggrecanase activity |
US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
EP1280922A2 (en) * | 2000-04-18 | 2003-02-05 | Millennium Pharmaceuticals, Inc. | 21953, a human prolyl oligopeptidase family member and uses thereof |
US20030083244A1 (en) * | 2000-04-26 | 2003-05-01 | Vernet Corine A.M. | Novel proteins and nucleic acids encoding same |
WO2001083782A2 (en) * | 2000-05-04 | 2001-11-08 | Sugen, Inc. | Novel proteases |
ATE317399T1 (en) | 2000-06-23 | 2006-02-15 | REGULATION OF HUMAN PROSTASIN-LIKE SERINE PROTEASE | |
EP1297154A2 (en) * | 2000-06-26 | 2003-04-02 | Bayer Aktiengesellschaft | Regulation of human caspase-1-like protease |
US20020137181A1 (en) * | 2000-07-18 | 2002-09-26 | Rachel Meyers | 14087, a novel serine protease molecule and uses therefor |
WO2002012461A2 (en) * | 2000-08-07 | 2002-02-14 | Bayer Aktiengesellschaft | Regulation of human membrane-type serine protease |
GB0020345D0 (en) * | 2000-08-17 | 2000-10-04 | Glaxo Group Ltd | Protein |
EP1311690B1 (en) * | 2000-08-22 | 2006-07-26 | Lexicon Genetics Incorporated | Human proteases and polynucleotides encoding the same |
AU2002215312A1 (en) * | 2000-09-29 | 2002-04-08 | Lexicon Genetics Incorporated | Human proteases and polynucleotides encoding the same |
JP2004528812A (en) * | 2000-10-12 | 2004-09-24 | フェリング ベスローテン フェンノートシャップ | Novel serine protease gene associated with DPPIV |
US20020119555A1 (en) * | 2000-12-22 | 2002-08-29 | Rajasehkar Bandaru | 53014, a human metalloprotease family member and uses therefor |
GB0101760D0 (en) * | 2001-01-23 | 2001-03-07 | Glaxo Group Ltd | Novel protein |
JP2004535166A (en) * | 2001-03-22 | 2004-11-25 | デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー | Nucleic acid molecule encoding serine protease CVSP14, encoded polypeptide and methods based thereon |
US7034134B2 (en) | 2001-04-26 | 2006-04-25 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
CA2447050A1 (en) * | 2001-05-14 | 2002-11-21 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
US7125701B2 (en) | 2001-07-27 | 2006-10-24 | Wyeth | Aggrecanase molecules |
WO2003027282A1 (en) * | 2001-09-24 | 2003-04-03 | Daiichi Fine Chemical Co., Ltd. | Adamts-15, -16, -17, -18 and -19 |
WO2003042379A2 (en) * | 2001-11-13 | 2003-05-22 | Universite De Liege | A new disintegrin and metalloproteinase with thrombospondin type i repeats polynucleotide and its encoded polypeptide |
AU2003238359A1 (en) * | 2002-01-28 | 2003-09-02 | Bayer Aktiengesellschaft | Regulation of human membrane-type serine protease |
EP2341350B1 (en) * | 2003-09-20 | 2017-11-08 | Electrophoretics Limited | Diagnostic method for brain damage-related disorders based on detection of dj-1 |
WO2005040792A2 (en) * | 2003-10-21 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with arginyl aminopeptidase (aminopeptidase b)-like 1 (rnpepl1) |
WO2005106021A1 (en) * | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 8 (dpp8) |
WO2005118632A1 (en) * | 2004-05-27 | 2005-12-15 | Vib Vzw | A NOVEL HUMAN CARD-ONLY PROTEIN THAT INHIBITS PRO-IL-1β MATURATION |
US8216582B2 (en) * | 2006-06-23 | 2012-07-10 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
CN101636179B (en) | 2006-11-07 | 2012-10-10 | 默沙东公司 | Antagonists of pcsk9 |
CA2680832A1 (en) | 2007-03-27 | 2008-10-02 | Merck & Co., Inc. | Method for detecting autoprocessed, secreted pcsk9 |
AR070315A1 (en) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | ANTIBODIES 1B20 ANTAGONISTS OF PCSK9 |
AR070316A1 (en) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN) |
CA3050455A1 (en) | 2008-11-03 | 2010-06-03 | Adc Therapeutics Sa | Antibodies that specifically block the biological activity of a tumor antigen |
WO2010068526A1 (en) | 2008-12-12 | 2010-06-17 | Merck Sharp & Dohme Corp. | Pcsk9 immunoassay |
WO2011053759A1 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Ax1 and ax189 pcsk9 antagonists and variants |
AU2010313324A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX213 and AX132 PCSK9 antagonists and variants |
WO2012129668A1 (en) | 2011-03-31 | 2012-10-04 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
JP6282597B2 (en) | 2012-01-09 | 2018-02-21 | アー・デー・ツェー・セラピューティクス・エス・アー | How to treat breast cancer |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
CN110352242A (en) | 2016-12-23 | 2019-10-18 | 哈佛大学的校长及成员们 | The gene editing of PCSK9 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999025373A1 (en) * | 1997-11-14 | 1999-05-27 | Millennium Pharmaceuticals, Inc. | Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase |
WO2000057903A2 (en) * | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | 48 human secreted proteins |
WO2002000860A2 (en) * | 2000-06-26 | 2002-01-03 | Sugen, Inc. | Novel proteases |
-
2001
- 2001-06-13 CA CA002411971A patent/CA2411971A1/en not_active Abandoned
- 2001-06-13 WO PCT/US2001/019178 patent/WO2001098468A2/en not_active Application Discontinuation
- 2001-06-13 EP EP01948379A patent/EP1292684A2/en not_active Withdrawn
- 2001-06-13 JP JP2002504617A patent/JP2004515217A/en active Pending
- 2001-06-13 AU AU2001269836A patent/AU2001269836A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999025373A1 (en) * | 1997-11-14 | 1999-05-27 | Millennium Pharmaceuticals, Inc. | Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase |
WO2000057903A2 (en) * | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | 48 human secreted proteins |
WO2002000860A2 (en) * | 2000-06-26 | 2002-01-03 | Sugen, Inc. | Novel proteases |
Non-Patent Citations (12)
Title |
---|
D'ANDREA A ET AL: "DEUBIQUITINATING ENZYMES A NEW CLASS OF BIOLOGICAL REGULATORS", CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, CRC PRESS, BOCA RATON, FL, US, vol. 33, no. 5, October 1998 (1998-10-01), pages 337 - 352, XP000943127, ISSN: 1040-9238 * |
DATABASE EMBL [online] 1 January 1998 (1998-01-01), B. LAUER ET AL: "Hypothetical 16.6 KDA protein (fragment)", XP002200355, Database accession no. AAG10401 * |
DATABASE EMBL [online] 11 September 2000 (2000-09-11), O. OHARA ET AL: "Homo sapiens mRNA for KIAA1594 protein, partial cds", XP002200358, Database accession no. AB046814 * |
DATABASE EMBL [online] 21 June 1999 (1999-06-21), S. ZHAO ET AL: "CITBI-E1-2646J3:TF CITBI-E1 Homo sapiens genomic clone 2646J3, genomic survey sequence", XP002200357, Database accession no. AQ626556 * |
DATABASE EMBL [online] 27 August 1995 (1995-08-27), T. FUJIWARA ET AL: "Human fetal brain cDNA Cdna 5'-END gen-184b02", XP002200356, Database accession no. D61366 * |
DATABASE EMBL [online] 6 September 2000 (2000-09-06), J. KIM ET AL: "ubiquitin-specific processing protease (Homo sapiens)", XP002200359, Database accession no. AAG10401 * |
FUJIWARA TSUTOMU ET AL: "Identification and chromosomal assignment of USP1, a novel gene encoding a human ubiquitin-specific protease", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 54, no. 1, 15 November 1998 (1998-11-15), pages 155 - 158, XP002153254, ISSN: 0888-7543 * |
J. KIM ET AL: "Discovery of a novel, paternally expressed Ubiquitin-specific processing protease gene through comparative analysis of an imprinted region of mouse chromosome 7 and human chromosome 19q13.4", GENOME RESEARCH, vol. 10, no. 8, August 2000 (2000-08-01), pages 1138 - 1147, XP002200354 * |
SLOPER-MOULD KATHERINE E ET AL: "Characterization and chromosomal localization of USP3, a novel human ubiquitin-specific protease.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 38, pages 26878 - 26884, XP002200352, ISSN: 0021-9258 * |
T. NAGASE ET AL: "Prediction of the coding sequences of unidentified human genes. XVIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro", DNA RESEARCH, vol. 7, 31 August 2000 (2000-08-31), pages 273 - 281, XP002200353 * |
UNPUBLISHED * |
YASUO KAJIMOTO ET AL: "cDNA Cloning and tissue distribution of a rat Ubiquitin carboxyl-terminal hydrolase PGP9.5", JOURNAL OF BIOCHEMISTRY., vol. 112, 1992, JAPANESE BIOCHEMICAL SOCIETY, TOKYO., JP, pages 28 - 32, XP002200351, ISSN: 0021-924X * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871914B2 (en) | 2007-08-23 | 2014-10-28 | Amgen, Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8871913B2 (en) | 2007-08-23 | 2014-10-28 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8883983B2 (en) | 2007-08-23 | 2014-11-11 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8889834B2 (en) | 2007-08-23 | 2014-11-18 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US9493576B2 (en) | 2007-08-23 | 2016-11-15 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8859741B2 (en) | 2007-08-23 | 2014-10-14 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US8981064B2 (en) | 2007-08-23 | 2015-03-17 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
US9266961B2 (en) | 2012-06-15 | 2016-02-23 | Genentech, Inc. | Anti-PCSK9 antibodies, formulations, dosing, and methods of use |
US9227956B2 (en) | 2013-04-17 | 2016-01-05 | Pfizer Inc. | Substituted amide compounds |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
US8999341B1 (en) | 2014-07-15 | 2015-04-07 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9034331B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9062105B1 (en) | 2014-07-15 | 2015-06-23 | Kymab Limited | Precision Medicine by targeting VEGF-A variants for treatment of retinopathy |
US9109034B1 (en) | 2014-07-15 | 2015-08-18 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US9187562B1 (en) | 2014-07-15 | 2015-11-17 | Kymab Limited | Methods for treating anaemia |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9303089B2 (en) | 2014-07-15 | 2016-04-05 | Kymab Limited | Methods of treating anaemia |
US9394568B2 (en) | 2014-07-15 | 2016-07-19 | Kymab Limited | Methods of treating anaemia |
US9428578B2 (en) | 2014-07-15 | 2016-08-30 | Kymab Limited | Methods of treating anaemia |
US9439963B2 (en) | 2014-07-15 | 2016-09-13 | Kymab Limited | Methods of treating anaemia |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
Also Published As
Publication number | Publication date |
---|---|
JP2004515217A (en) | 2004-05-27 |
CA2411971A1 (en) | 2001-12-27 |
AU2001269836A1 (en) | 2002-01-02 |
EP1292684A2 (en) | 2003-03-19 |
WO2001098468A2 (en) | 2001-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001098468A3 (en) | Proteases | |
WO2003052075A3 (en) | Enzymes | |
WO2002008396A3 (en) | Human proteases | |
WO2002063005A3 (en) | Lipid-associated molecules | |
WO2001096547A3 (en) | Human kinases | |
WO2001060991A3 (en) | Human kinases | |
WO2002018557A3 (en) | Human kinases | |
WO2002083709A3 (en) | Kinases and phosphatases | |
WO2001072777A3 (en) | Human transcription factors | |
WO2002038744A3 (en) | Proteases | |
WO2003042357A3 (en) | Enzymes | |
WO2001071004A3 (en) | Proteases | |
WO2001096546A3 (en) | Protein phosphatases | |
WO2002026950A3 (en) | Transferases | |
WO2002097060A3 (en) | Carbohydrate-associated proteins | |
WO2001085942A3 (en) | Cytoskeleton-associated proteins | |
WO2002010363A3 (en) | Protein phosphatases | |
WO2000042201A3 (en) | Human peptidases | |
WO2002020736A3 (en) | Proteases | |
WO2001046443A3 (en) | Proteases | |
WO2002033099A3 (en) | Human kinases | |
WO2001081555A3 (en) | Human kinases | |
WO2002024924A3 (en) | Protein phosphatases | |
WO2002066646A3 (en) | Neurotransmission-associated proteins | |
WO2002064795A3 (en) | Putative human enzymes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2411971 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 504617 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001948379 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001948379 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10311035 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001948379 Country of ref document: EP |